Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Authors:
Open Access
- 25 May 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1190379
Abstract
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.Keywords
Funding Information
- Jackson Laboratory
This publication has 173 references indexed in Scilit:
- A Human In Vitro Whole Blood Assay to Predict the Systemic Cytokine Response to Therapeutic Oligonucleotides Including siRNAPLOS ONE, 2013
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeProceedings of the National Academy of Sciences, 2013
- A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen ReceptorCancer Research, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to ApoptosisThe Journal of Immunology, 2011
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cellsBlood, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokineticsJournal of Molecular Biology, 1999